Skip to search formSkip to main contentSkip to account menu

monafram

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Monoclonal AntibodiesPeptide Fragments

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Red blood cells (dis)aggregation: effect of inhibition of fibrinogen binding
There are complex interactions between blood cells, and erythrocytes may enhance platelet aggregation. However, there is a lack… 
2011
2011
EFFICACY AND SAFETY OF GLYCOPROTEIN IIB/IIIA BLOCKER MONOFRAM IN CORONARY STENTING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Aim. To study of efficacy and safety of glycoprotein IIb/IIIa blocker monafram in acute ST-segment elevation myocardial… 
2010
2010
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Glycoprotein (GP) llb-llla anagonist monafram is the F(ab)2 fragments of anti GP llb llla monoclonal antibody FraMon (CRC64… 
2005
2005
[Results of clinical trials of a novel glycoprotein IIb-IIIa antagonist framon in high-risk coronary angioplasty].
New glycoprotein (GP) IIb-IIIa antagonist preparation framon (Monafram), is the F(ab')(2) fragment of a monoclonal antibody… 
2004
2004
[Antiplatelet effects of glycoproteins IIb-IIIa antagonist monafram].
First Russian glycoprotein (GP) IIb-IIIa antagonist, preparation Monafram, is the F(ab')2 fragment of anti-GP IIb-IIIa monoclonal…